Work Area: IP public policy

Latest content

Discretionary denials impact US life sciences IP strategies, but not as much as might be thought

SCOTUS refuses to consider NHK-Fintiv legal challenges, with significant implications for PTAB actions

20 January 2022

USPTO reports strong finances despite a fall in patent filings

Increased fees helped the office's budget escape unscathed from a drop in applications, and the agency expects 1.5% growth in patenting this year

19 January 2022

Japan mulls paying companies to keep sensitive patents under wraps

Economic security law proposed by Japanese government would place restrictions on disclosing patents related to sensitive technologies and innovations

19 January 2022

WHO’s vaccine successes show significance of Moderna covid IP pledge

African tech transfer hub is making fast progress in replicating the approved mRNA jab

18 January 2022

Draft Biden SEP policy favours implementers, but even they may still flock to other jurisdictions

Finnegan attorneys Erik Puknys and Michelle Rice explain that while the proposed DOJ/NIST/USPTO FRAND framework is good for implementers, it may not be enough to make the US stand out in global forum competition

17 January 2022

Tencent, Vivo among biggest risers as Chinese patent grants continue to grow

The number of invention patents and utility models issued by the CNIPA both surged by more than 30% last year, while PCT filings levelled off

11 January 2022

AbbVie heads to the ITC in dramatic final battle over Humira biosimilars

Chicago-based company seeking to exclude Alvotech’s adalimumab product from the US market for alleged trade secret misappropriation

10 January 2022

Vidal USPTO Director confirmation vote cancelled, but not due to opposition to her appointment

The Senate Judiciary Committee is all set to endorse her appointment but has been delayed in doing thanks to a funeral and a riot’s anniversary

06 January 2022

Landmark Dutch appeal court decision reduces risk of third-party damages against pharma patentees

The appellate ruling overturns a recent lower court judgment which exposed life sciences IP plaintiffs to significant additional dangers from health insurer lawsuits

06 January 2022

How looming patent cliffs are impacting pharma IP strategies

Major IP expiries on the horizon are not only shaping pharma dealmaking patterns, but are likely to lead to further patent thicket disputes.

05 January 2022

Get unlimited access to all IAM content